Cobenfy is the first drug to treat the disease that targets the brain's cholinergic receptors


Washington: The US Food and Drug Administration has approved a new drug for adults with schizophrenia.
The drug, commonly known as Cobenfy, is the first drug to treat the disease that targets the brain's cholinergic receptors, rather than the dopamine receptors that are the traditional focus of treatment.
“Schizophrenia is the leading cause of disability worldwide,” said Dr. Tiffany Farshion in the Institute's Department of Neuroscience.
He stated the drug represents the first new approach to treating schizophrenia. It offers a new alternative to the antipsychotic drugs that have previously been prescribed to people with schizophrenia.
It is pertinent to note that schizophrenia is a severe, chronic mental illness that often impairs a person's quality of life.
US actress Diane Keaton, star of ‘Annie Hall,’ passes away at 79
- 15 گھنٹے قبل
Pakistan–Saudi Arabia defence pact: the dawn of a new era
- 14 گھنٹے قبل

49ers set to start QB Jones again; Pearsall out
- 13 گھنٹے قبل
Four candidates submit nomination papers for KP CM slot
- 10 گھنٹے قبل

Vegetable prices in Lahore soar once again; tomatoes reach Rs500 per kg
- 8 گھنٹے قبل
Pakistan 313-5 at close of first day against South Africa
- 15 گھنٹے قبل

Messi sits out Argentina victory in Miami friendly
- 13 گھنٹے قبل
China, North Korea to strengthen strategic cooperation, KCNA says
- 14 گھنٹے قبل
Over 200 Afghan Taliban, Khawarij killed; 23 Pak Army soldiers martyred: ISPR
- 14 گھنٹے قبل
Russia, Pakistan conclude Druzhba 2025 joint military exercises
- 15 گھنٹے قبل
Taylor Swift’s ‘Life of a Showgirl’ storms UK charts, sets new records
- 15 گھنٹے قبل
Bitcoin extends decline to $104,782 as Trump escalates US-China trade war
- 14 گھنٹے قبل